BYK 321084

Drug Profile

BYK 321084

Alternative Names: BYK321084; PDE4 inhibitor - Nycomed; PDE4 inhibitor – Takeda; PDE4i – Nycomed; TAK-084; Type 4 cyclic nucleotide phosphodiesterase inhibitor – Nycomed

Latest Information Update: 29 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nycomed
  • Developer Takeda Pharmaceuticals International GmbH
  • Class Anti-inflammatories; Antipsoriatics; Phenanthridines; Skin disorder therapies
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Inflammation; Plaque psoriasis

Most Recent Events

  • 29 Apr 2016 No recent reports on development identified - Phase-I for Inflammation in Europe (Topical)
  • 29 Apr 2016 No recent reports on development identified - Phase-I for Plaque psoriasis in Germany (Topical)
  • 29 Apr 2016 Primary efficacy data from a phase I trial in Plaque psoriasis released by Takeda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top